
OCU410 Gene Therapy Slows Geographic Atrophy in Trial
A single injection of OCU410 gene therapy slowed geographic atrophy growth by about 32% in a Phase 2 trial. Here’s what it could mean for dry AMD.
By
Lana Pine| Published on November 19, 2026
Fact checked by:
Afton Woodward4 min read
A single injection of an investigational gene therapy slowed the growth of geographic atrophy, an advanced form of dry age-related macular degeneration (AMD), by about 32% over one year. The Phase 2 results were presented at the Retina Society 2026 annual meeting in Los Angeles in September.
The therapy, called OCU410 and developed by Ocugen, is given once as an injection beneath the retina. The approved treatments for geographic atrophy, by contrast, require repeated injections into the eye.
How Geographic Atrophy Damages Central Vision
Geographic atrophy is a late stage of dry AMD in which patches of cells in the macula gradually die. The macula is the part of the retina responsible for sharp central vision. These damaged patches, called lesions, grow larger over time, and the vision loss they cause cannot be reversed. As the disease progresses, people may have trouble reading, recognizing faces or driving.
Two drugs are FDA approved to slow geographic atrophy: pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay). Both are injected into the eye on an ongoing basis, which can be a burden for older patients and their caregivers.
How Does OCU410 Work?
OCU410 is a gene therapy that uses a modified, harmless virus called AAV5 to deliver a gene called RORA into retinal cells. Ocugen calls it a “modifier” gene therapy. Rather than fixing a single faulty gene, it is intended to influence several biological processes involved in the disease. Because it is designed as a one-time treatment, it could reduce the need for frequent eye injections if it proves effective in larger trials.
One Injection Slowed Lesion Growth by About a Third
The ArMaDa trial randomly assigned 51 adults with geographic atrophy to one of three groups: a medium dose of OCU410, a high dose, or no treatment. After 12 months, 45 participants had enough follow-up data to be evaluated.
On average, lesions in the medium-dose group grew 1.42 square millimeters, compared with 2.15 square millimeters in the untreated group. Investigators reported a 32.3% reduction in lesion growth through 12 months in their main analysis, which measured change from each patient’s starting point. The high dose did not show a meaningful benefit.
Some patients had lesions in the size range planned for the Phase 3 trial, 2.5 to 17.5 square millimeters. In that group, the medium dose slowed lesion growth by 31.5%. Treated eyes also lost 27% less of the ellipsoid zone, a layer visible on retinal scans that reflects the health of light-sensing photoreceptor cells.
Safety Results From the Trial
OCU410 was well tolerated, and researchers reported no serious adverse events related to the drug.
Why These Results Are Still Early
The findings are promising but preliminary. The trial was small, and it was open-label, meaning participants and doctors knew who received treatment. The statistical results are considered nominal, and the subgroup analysis was exploratory, so they need to be confirmed in a larger study.
The presentation also did not report visual acuity results. It is not yet known whether slowing lesion growth with OCU410 will help people keep more of their vision. The results were presented at a medical meeting and have not yet been published in a peer-reviewed journal.
Phase 3 Trial Is the Next Step
The researchers concluded that the medium dose should be tested in a phase 3 trial. “I’m looking forward to the results of the ongoing phase 3 confirmatory study,” said Raj K. Maturi, M.D., of Retina Partners Midwest in Indianapolis, who presented the findings.
OCU410 is not FDA approved. People with geographic atrophy should talk with a retina specialist about current treatment options and whether a clinical trial might be a good fit.

